Cremolini, C., Marmorino, F., Bergamo, F., Aprile, G., Salvatore, L., Masi, G., Dell'Aquila, E., Antoniotti, C., Murgioni, S., Allegrini, G., Borelli, B., Gemma, D., Casagrande, M., Granetto, C., Delfanti, S., Di Donato, S., Schirripa, M., Sensi, E., Tonini, G., Lonardi, S., Fontanini, G., Boni, L., & Falcone, A. (2019). phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. European journal of cancer, 109, 175–182. http://access.bl.uk/ark:/81055/vdc_100084047788.0x000028